Recommendations for action in patients with Crohn's disease who started treatment with adalimumab: A fast guide;Recomendaciones de actuación en pacientes con enfermedad de Crohn que empiezan tratamiento con adalimumab: Una guía rápida

Gastroenterologia y Hepatologia

Volumn 31, Issue 10, 2008, Pages 693-697

  Cabriada, José Luis ^a   Sánchez, Valle García ^b   Gomollón, Fernando ^c   Hinojosa, Joaquín ^d   San Román, Antonio López ^e   Mendoza, Juan Luis ^f   Mínguez, Miguel ^g   Ricart, Elena ^h   Saro, Cristina ⁱ  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL DE SAGUNTO   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL DE CABUEÑES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIVIRUS AGENT; BCG VACCINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; PREDNISONE; RIFAMPICIN; TUMOR NECROSIS FACTOR INHIBITOR;

ANAMNESIS; ANUS DISEASE; AUTOIMMUNITY; BREATHING DISORDER; CLINICAL EVALUATION; COUGHING; CROHN DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; FEVER; HEPATITIS B; HEPATITIS C; HUMAN; PHYSICAL EXAMINATION; PREGNANCY TEST; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TUBERCULOSIS; VACCINATION; WEIGHT REDUCTION;

EID: 60149086668     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/s0210-5705(08)75817-5     Document Type: Review

References (34)

1. HUMIRA Ficha Técnica de Producto. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/humira/H-481-PI-es.pdf
2. Keane J, Gershon S, Wise RP, Mirabil-Levens E, Kasznica J, Schwiterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
3. Gómez-Reino JJ, Carmona L, Rodríguez-Valverde V, Martín-Mola E, Moreno C, et al, on behalf of the BIOBADASER Group. An active surveillance of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors indicates significant tuberculosis risk increase. Arthritis Rheum. 2003;48:2122-7.
4. López-San Román A, Obrador A, Fortún J, Muñoz P, Gassull MA. Recomendaciones sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Actualización 2005. Gastroenterol Hepatol. 2006;29:85-92.
5. Grupo de Trabajo sobre Tuberculosis. Consenso nacional para el control de la tuberculosis en España. Med Clin (Barc). 1992;98:24-31.
6. Grupo de Trabajo del área TIR de SEPAR. Recomendaciones SEPAR. Normativa sobre la prevención de la tuberculosis. Arch Bronconeumol. 2002;38:441-51
7. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:221S-47S [update 2001;164:1319-20].
8. Rodríguez-Valverde V, Cáliz Cáliz R, Álvaro-Gracia Álvaro JM, Marenco de la Fuente JL, Mulero Mendoza J, Tornero Molina J, et al. III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide. J. Reumatol Clin. 2006;2 Suppl 2:52-9.
9. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57:549-58.
10. Toruner M, Loftus EW, Harmsen WS, Zinmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-36.
11. Burmester G, Mease PJ, Dijkmans BA, Gordon KB, Lovell DJ, Kent JD, et al. Adalimumab clinical trial safety in multiple indications and reduction in mortality in rheumatoid arthritis. Arthritis Rheum. 2006;59 Suppl 9:232.
12. Colombel JF, Panaccione R, Sandborn WJ, Rutgeerts P, Hanauer SB, Reinisch W, et al. Global safety of adalimumab in Crohn's disease clinical trials. J Crohn's Colitis. 2008;Suppl 2:8.
13. Esteve M, Saro C, González-Huix F, Suárez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-5.
14. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) theraphy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis. 2004;63:18-24.
15. Sánchez Muñoz D, Hoyas Pablos E, Ramírez Martín del Campo M, Núñez Hospital D, Guerrero Jiménez P. Gestación a término en paciente con enfermedad de Crohn en tratamiento con adalimumab. Gastroenterol Hepatol. 2005;28:435-36.
16. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (HUMIRA) for Crohn's disease in pregnacy. Inflamm Bowel Dis. 2006;12:827-8.
17. Chambers CD, Johnson DL, Jones KL, Otis Collaborative Research Group. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoinmume diseases in pregnacy project. J Am Acad Dermatol. 2007;2 Suppl 2:10-39.
18. Gelinck LBS, Van der Bijl AE, Beyer WEP, Visser LG, Huizinga TWJ, Van Hogezand RA, et al. The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67:713-6.
19. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272-9.
20. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med. 2007;146:829-38.
21. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: results of the CHARM trial. Gastroenterology. 2007;132:52-65.
22. Hanauer SB, Sandborn WJ, Macintosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology. 2006;130:323-33.
23. Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, et al. Efficacy and safety of short term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther. 2007;25:409-18.
24. Sandborn WJ, Hanauer SB, Rutgeerts PJ, Fedorak RN, Lukas M, Macintosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC-II trial. Gut. 2007;56:1232-9.
25. Gomollón F, Hinojosa J, García S, Bastida G, Saro C, Cabriada JL, et al. Eficacia y seguridad del tratamiento con adalimumab a largo plazo en pacientes con enfermedad de Crohn luminal con pérdida de respuesta o intolerancia infliximab. Gastroenterol Hepatol. 2007;30:183-4.
26. Hinojosa J, Gomollón F, García S, Bastida G, Saro C, Cabriada JL, et al. Long-term efficacy of adalimumab treatment in patients with moderately to severely active luminal Crohn's disease who lost response or showed intolerance to infliximab. Gut. 2007;56 Suppl 3:153.
27. Mendoza JL. Revisión clínica: adalimumab en gastroenterología. Disponible en: http://www.geteccu.org/recursos/rec23. pdf
28. Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. BioDrugs. 2007;21:125-32.
29. Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Lomax KG, et al. Adalimumab mantains long-term remission in Crohn's disease through 2 years. J Crohn's Colitis. 2008; Suppl 2:5.
30. Loftus EV, Colombel JF, Panaccione R, Feagan BG, Pollack PF, Chao J, et al. Adalimumab sustains quality of life improvements in patients with Crohn's disease: 2-year data from CHARM. J Crohn's Colitis. 2008; Suppl 2:28.
31. Gomollón F, Hinojosa J, Nós P, Peñate M, Ceballos D, Gassull MA. Long-term results of adalimumab treatment in subjects with moderately to severely active fistulizing Crohn's disease who have failed response or showed intolerance to infliximab. Gut. 2007;56 Suppl 3:152.
32. Rutgeerts P, Colombel JF, Sandborn WJ, Hanauer SB, Kent JD, Pollack PF. Induction, maintenance and sustainability of healing of draining fistulas in patients with Crohn's disease: results of the CHARM Study. Gut. 2006;55 Suppl 5:131.
33. Colombel JF, Kamm MA, Schwartz DA, Sandborn WJ, Li JM, Lomax KG, et al. Long-term fistula healing and response with adalimumab treatment: 2 year data from CHARM including one year open-label extension. J Crohn's Colitis. 2008;11 Suppl 2:19.
34. Loftus EV, Colombel JF, Panaccione R, Feagan BG, Kamm MA, Pollack PF, et al. Sustainability of adalimumab in improving the quality of life of patients with fistulizing Crohn's disease: 2-year data from CHARM. J Crohn's Colitis. 2008;Suppl 2:42-124.